^
Association details:
| Biomarker: | HGF elevation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) + pazopanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Circulating Levels of the Interferon-gamma-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy
Published date:
06/07/2021
Excerpt:
In the present study we have shown that high basal circulating levels of HGF, CXCL10, CXCL11 and IL-6 are associated with a lack of response to sunitinib and/or pazopanib, and a worse outcome in mRCC patients.
DOI:
10.3390/cancers13112849
